IDEXX Laboratories, Inc. (NASDAQ:IDXX) Stock Position Lowered by Taikang Asset Management Hong Kong Co Ltd

Taikang Asset Management Hong Kong Co Ltd reduced its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 42.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 10,125 shares of the company's stock after selling 7,579 shares during the period. Taikang Asset Management Hong Kong Co Ltd's holdings in IDEXX Laboratories were worth $4,186,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Insight Wealth Strategies LLC raised its holdings in IDEXX Laboratories by 230.5% in the 4th quarter. Insight Wealth Strategies LLC now owns 10,096 shares of the company's stock worth $4,174,000 after acquiring an additional 7,041 shares during the period. Larson Financial Group LLC grew its stake in shares of IDEXX Laboratories by 17,238.5% during the third quarter. Larson Financial Group LLC now owns 2,254 shares of the company's stock worth $1,139,000 after purchasing an additional 2,241 shares during the period. Geode Capital Management LLC grew its stake in IDEXX Laboratories by 1.8% in the third quarter. Geode Capital Management LLC now owns 2,259,537 shares of the company's stock valued at $1,138,732,000 after acquiring an additional 40,349 shares during the period. Y Intercept Hong Kong Ltd acquired a new stake in IDEXX Laboratories in the 3rd quarter valued at approximately $1,263,000. Finally, Sax Wealth Advisors LLC grew its stake in IDEXX Laboratories by 76.3% in the fourth quarter. Sax Wealth Advisors LLC now owns 1,426 shares of the company's stock valued at $590,000 after purchasing an additional 617 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company's stock.

Remove Ads

IDEXX Laboratories Stock Down 1.6 %

Shares of NASDAQ:IDXX traded down $6.67 during trading on Friday, hitting $415.87. The company's stock had a trading volume of 470,167 shares, compared to its average volume of 581,913. IDEXX Laboratories, Inc. has a fifty-two week low of $398.50 and a fifty-two week high of $548.88. The business has a 50 day moving average price of $437.07 and a two-hundred day moving average price of $442.90. The company has a market capitalization of $33.71 billion, a PE ratio of 38.98, a P/E/G ratio of 3.41 and a beta of 1.39. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31.

Insider Activity

In other IDEXX Laboratories news, EVP George Fennell sold 9,986 shares of the stock in a transaction on Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the sale, the executive vice president now owns 8,176 shares in the company, valued at approximately $3,781,645.28. This represents a 54.98 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director M Anne Szostak sold 3,000 shares of the company's stock in a transaction on Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the sale, the director now owns 3,061 shares of the company's stock, valued at approximately $1,426,242.34. The trade was a 49.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 2.11% of the company's stock.

Wall Street Analysts Forecast Growth

IDXX has been the topic of a number of analyst reports. Bank of America increased their price objective on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a research note on Tuesday, February 4th. Barclays boosted their target price on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an "overweight" rating in a report on Tuesday, February 4th. StockNews.com lowered shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Tuesday. Leerink Partners began coverage on IDEXX Laboratories in a report on Monday, December 2nd. They issued an "outperform" rating and a $500.00 price objective for the company. Finally, Leerink Partnrs raised shares of IDEXX Laboratories to a "strong-buy" rating in a research report on Monday, December 2nd. Four analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $533.75.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.